Skip to content
Clinical Trials – home
Therapeutic area

Neoplasms benign, malignant and unspecified (incl cysts and polyps) – page 184

  • 3 901 clinical trials
  • 1 548 recruiting
  • 705 conditions
  • 31 countries

Conditions in this area

705 conditions with trials, the busiest first

Clinical trials in Neoplasms benign, malignant and unspecified (incl cysts and polyps)

3 901 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

3 901 clinical trials

Follicular lymphoma

Not recruiting

Study on Rituximab and Lenalidomide for Patients with Relapsed or Refractory Follicular Lymphoma Not Eligible for Transplant

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Rituximab
  • Sponsor:Fondazione Italiana Linfomi Ets

Hodgkin's disease+2

Not recruiting

Study on the Safety of HSP-CAR30 Immunotherapy for Patients with Relapsed or Refractory CD30+ Hodgkin and Non-Hodgkin Lymphoma

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:HSP-CAR30
  • Sponsor:Fundacio Institut De Recerca De L'Hospital De La Santa Creu I Sant Pau

Study on Reducing Treatment Intensity for Patients with HPV-Positive Oropharyngeal Cancer Using Cisplatin and Carboplatin

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Cardiff University

Colon cancer

Not recruiting

Study on Chemotherapy with Levoleucovorin, Capecitabine, and Folinic Acid for Patients Aged 70+ After Stage III Colon Cancer Surgery

Registered drugNo placebo
Countries:FranceFrance
  • Participants:65+ years
  • Substances:Capecitabine
  • Sponsor:Fondation Franc.Cancerologie Digestive

Study of Axicabtagene Ciloleucel for Patients with Relapsed or Refractory Primary Mediastinal B-Cell Lymphoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Axicabtagene Ciloleucel
  • Sponsor:Universitaet Muenster

Study of Retifanlimab Combined with Carboplatin, Cisplatin and Etoposide Before Surgery in Patients with Resectable Merkel Cell Carcinoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Fondazione GONO G.I.

Soft tissue sarcoma

Not recruiting

Study of Cirtuvivint for Patients with Advanced Soft-Tissue Sarcomas as a Second-Line Treatment

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Cirtuvivint
  • Sponsor:Asociacion Europea Y Latinoamericana SELNET Para La Investigacion En Sarcomas

Soft tissue sarcoma

Not recruiting

Study of PM14 Alone and with Radiotherapy for Patients with Advanced Soft Tissue Sarcomas and Other Solid Tumors

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Ecubectedin
  • Sponsor:Asoc Grupo Espanol De Investigacion En Sarcomas

Study of Fuzuloparib, Abiraterone Acetate, and Prednisone for First-Line Treatment in Patients with Metastatic Castration-Resistant Prostate Cancer

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone Acetate
  • Sponsor:Jiangsu Hengrui Pharmaceuticals Co. Ltd.

Study on Survival in Patients with Resectable Pancreatic Cancer Using Irinotecan, Fluorouracil, Calcium Folinate, and Oxaliplatin Combination Therapy

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:La Fundacion Para La Gestion De La Investigacion Biomedica De Cadiz

Study on Methadone Hydrochloride and Drug Combination for Patients with Advanced Metastatic Colorectal Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Fluorouracil
  • Sponsor:AIO-Studien gGmbH

Study on Stopping Nilotinib for Chronic Myeloid Leukemia Patients After Previous Unsuccessful Attempts to Stop Tyrosine Kinase Inhibitors

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Nilotinib
  • Sponsor:Heidelberg University

Substances studied in this area

The therapies tested most often in Neoplasms benign, malignant and unspecified (incl cysts and polyps) trials.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.